Next Century Growth Investors LLC increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 112.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 343,661 shares of the company's stock after acquiring an additional 181,842 shares during the period. Next Century Growth Investors LLC's holdings in TransMedics Group were worth $9,258,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Sei Investments Co. acquired a new position in shares of TransMedics Group during the 1st quarter valued at about $260,000. Rhumbline Advisers increased its holdings in shares of TransMedics Group by 6.9% during the 1st quarter. Rhumbline Advisers now owns 25,205 shares of the company's stock valued at $679,000 after acquiring an additional 1,621 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of TransMedics Group by 68.2% during the 1st quarter. MetLife Investment Management LLC now owns 15,561 shares of the company's stock valued at $419,000 after acquiring an additional 6,307 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in TransMedics Group in the 1st quarter valued at approximately $257,000. Finally, HighTower Advisors LLC acquired a new stake in TransMedics Group in the 1st quarter valued at approximately $250,000. Institutional investors and hedge funds own 81.46% of the company's stock.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded down $1.22 during midday trading on Friday, hitting $53.22. 1,575 shares of the company were exchanged, compared to its average volume of 440,990. The company has a debt-to-equity ratio of 0.70, a current ratio of 4.18 and a quick ratio of 3.41. TransMedics Group, Inc. has a 52 week low of $10.00 and a 52 week high of $56.00. The firm has a 50 day simple moving average of $42.31 and a 200-day simple moving average of $30.83.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 1,976 shares of the firm's stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $50.22, for a total transaction of $99,234.72. Following the completion of the transaction, the insider now owns 1,300 shares in the company, valued at approximately $65,286. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other TransMedics Group news, insider Tamer I. Khayal sold 1,976 shares of TransMedics Group stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $50.22, for a total value of $99,234.72. Following the completion of the transaction, the insider now owns 1,300 shares in the company, valued at approximately $65,286. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP John F. Carey sold 3,320 shares of TransMedics Group stock in a transaction on Monday, June 27th. The shares were sold at an average price of $32.59, for a total value of $108,198.80. Following the completion of the transaction, the vice president now owns 379 shares of the company's stock, valued at approximately $12,351.61. The disclosure for this sale can be found here. Insiders sold 181,628 shares of company stock worth $7,115,693 in the last 90 days. 8.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have issued reports on TMDX shares. JPMorgan Chase & Co. raised TransMedics Group from a "neutral" rating to an "overweight" rating and raised their target price for the company from $26.00 to $48.00 in a report on Tuesday, August 2nd. Canaccord Genuity Group raised their target price on TransMedics Group from $46.00 to $58.00 in a report on Thursday, August 4th. Morgan Stanley raised their target price on TransMedics Group from $34.00 to $37.00 and gave the company an "equal weight" rating in a report on Wednesday, August 3rd. Oppenheimer raised their target price on TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. Finally, Cowen lifted their price objective on TransMedics Group from $39.00 to $45.00 and gave the stock an "outperform" rating in a report on Tuesday, July 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $46.00.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

• Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
• Prepare For A Record-Setting Quarter For Cyber Security Stocks
• The Auto Market Is Slowly Recovering, These Stocks May Outperform
• Is DocuSign On The Verge Of A Major Reversal?
• Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
• Are These Green Energy Companies Right For Your Portfolio?

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating).

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.